Clinical Trials
3 trialsNCT01520870 2021-07-06
Safety and Efficacy of PF-299804 (Dacomitinib), a Pan-HER Irreversible Inhibitor, in Patients With Recurrent Glioblastoma With EGFR Amplification or Presence of EGFRvIII Mutation. A Phase II CT.
Grupo Español de Investigación en Neurooncología
Phase 2 Completed
NCT04675008 2021-01-05
Central Nervous System(CNS) Efficacy of Dacomitinib
Samsung Medical Center
Phase 2 Unknown
NCT02047747 2016-09-22
A Phase II Study of Dacomitinib in Progressive Brain Metastases
University of California, San Diego
Phase 2 Terminated